Managing regulatory T cells to improve cancer immunotherapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Regulatory T cells (Tregs) are increased in peripherally circulating blood cells and in the solid tumor masses of patients afflicted with many different cancer histologies. Cancer Tregs not only are capable of impeding endogenous protective anti-tumor immunity from optimal functioning but are also capable of impeding the efficacy of anti-cancer immunotherapy. Tumor-associated Tregs represent heterogeneous populations, differing by their origins and in their mechanisms used to impede anti-tumor immunity. Their properties can differ compared to those in peripheral circulation. Most studies now report that Treg content in the tumor inversely correlates with survival or therapeutic response, but a few reports suggest that Tregs are beneficial to patients with certain types of cancers. Therapeutic strategies to manage Treg capacity to mediate immune dysfunction include depletion, regulatory functional blockade, differentiation blockade, altering trafficking, differentiation diversion, or raising the threshold of anti-cancer effector cells for Treg-mediated regulation. Several clinical trials have shown the feasibility and relative safety of managing Tregs in human cancer, although treatment effects are modest. This chapter will review contemporary knowledge of Tregs in cancers, including origins, mechanisms of action, interactions with other immune cells and strategies for therapeutic management, addresses the major questions facing the field and suggests additional important areas for future research. The focus is on CD4+CD25+Foxp3+ Tregs, but other cancer-associated regulatory cells will be addressed in brief.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy: Paradigms, Practice and Promise
PublisherSpringer New York
Pages281-314
Number of pages34
Volume9781461447320
ISBN (Print)9781461447320, 1461447313, 9781461447313
DOIs
StatePublished - May 1 2013

Fingerprint

Regulatory T-Lymphocytes
Immunotherapy
Neoplasms
Immunity
Therapeutics
Blood Cells
Histology
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Curiel, T. J. (2013). Managing regulatory T cells to improve cancer immunotherapy. In Cancer Immunotherapy: Paradigms, Practice and Promise (Vol. 9781461447320, pp. 281-314). Springer New York. https://doi.org/10.1007/978-1-4614-4732-0_9

Managing regulatory T cells to improve cancer immunotherapy. / Curiel, Tyler J.

Cancer Immunotherapy: Paradigms, Practice and Promise. Vol. 9781461447320 Springer New York, 2013. p. 281-314.

Research output: Chapter in Book/Report/Conference proceedingChapter

Curiel, TJ 2013, Managing regulatory T cells to improve cancer immunotherapy. in Cancer Immunotherapy: Paradigms, Practice and Promise. vol. 9781461447320, Springer New York, pp. 281-314. https://doi.org/10.1007/978-1-4614-4732-0_9
Curiel TJ. Managing regulatory T cells to improve cancer immunotherapy. In Cancer Immunotherapy: Paradigms, Practice and Promise. Vol. 9781461447320. Springer New York. 2013. p. 281-314 https://doi.org/10.1007/978-1-4614-4732-0_9
Curiel, Tyler J. / Managing regulatory T cells to improve cancer immunotherapy. Cancer Immunotherapy: Paradigms, Practice and Promise. Vol. 9781461447320 Springer New York, 2013. pp. 281-314
@inbook{0b7744a089b44dd98a31b386c6fea282,
title = "Managing regulatory T cells to improve cancer immunotherapy",
abstract = "Regulatory T cells (Tregs) are increased in peripherally circulating blood cells and in the solid tumor masses of patients afflicted with many different cancer histologies. Cancer Tregs not only are capable of impeding endogenous protective anti-tumor immunity from optimal functioning but are also capable of impeding the efficacy of anti-cancer immunotherapy. Tumor-associated Tregs represent heterogeneous populations, differing by their origins and in their mechanisms used to impede anti-tumor immunity. Their properties can differ compared to those in peripheral circulation. Most studies now report that Treg content in the tumor inversely correlates with survival or therapeutic response, but a few reports suggest that Tregs are beneficial to patients with certain types of cancers. Therapeutic strategies to manage Treg capacity to mediate immune dysfunction include depletion, regulatory functional blockade, differentiation blockade, altering trafficking, differentiation diversion, or raising the threshold of anti-cancer effector cells for Treg-mediated regulation. Several clinical trials have shown the feasibility and relative safety of managing Tregs in human cancer, although treatment effects are modest. This chapter will review contemporary knowledge of Tregs in cancers, including origins, mechanisms of action, interactions with other immune cells and strategies for therapeutic management, addresses the major questions facing the field and suggests additional important areas for future research. The focus is on CD4+CD25+Foxp3+ Tregs, but other cancer-associated regulatory cells will be addressed in brief.",
author = "Curiel, {Tyler J}",
year = "2013",
month = "5",
day = "1",
doi = "10.1007/978-1-4614-4732-0_9",
language = "English (US)",
isbn = "9781461447320",
volume = "9781461447320",
pages = "281--314",
booktitle = "Cancer Immunotherapy: Paradigms, Practice and Promise",
publisher = "Springer New York",

}

TY - CHAP

T1 - Managing regulatory T cells to improve cancer immunotherapy

AU - Curiel, Tyler J

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Regulatory T cells (Tregs) are increased in peripherally circulating blood cells and in the solid tumor masses of patients afflicted with many different cancer histologies. Cancer Tregs not only are capable of impeding endogenous protective anti-tumor immunity from optimal functioning but are also capable of impeding the efficacy of anti-cancer immunotherapy. Tumor-associated Tregs represent heterogeneous populations, differing by their origins and in their mechanisms used to impede anti-tumor immunity. Their properties can differ compared to those in peripheral circulation. Most studies now report that Treg content in the tumor inversely correlates with survival or therapeutic response, but a few reports suggest that Tregs are beneficial to patients with certain types of cancers. Therapeutic strategies to manage Treg capacity to mediate immune dysfunction include depletion, regulatory functional blockade, differentiation blockade, altering trafficking, differentiation diversion, or raising the threshold of anti-cancer effector cells for Treg-mediated regulation. Several clinical trials have shown the feasibility and relative safety of managing Tregs in human cancer, although treatment effects are modest. This chapter will review contemporary knowledge of Tregs in cancers, including origins, mechanisms of action, interactions with other immune cells and strategies for therapeutic management, addresses the major questions facing the field and suggests additional important areas for future research. The focus is on CD4+CD25+Foxp3+ Tregs, but other cancer-associated regulatory cells will be addressed in brief.

AB - Regulatory T cells (Tregs) are increased in peripherally circulating blood cells and in the solid tumor masses of patients afflicted with many different cancer histologies. Cancer Tregs not only are capable of impeding endogenous protective anti-tumor immunity from optimal functioning but are also capable of impeding the efficacy of anti-cancer immunotherapy. Tumor-associated Tregs represent heterogeneous populations, differing by their origins and in their mechanisms used to impede anti-tumor immunity. Their properties can differ compared to those in peripheral circulation. Most studies now report that Treg content in the tumor inversely correlates with survival or therapeutic response, but a few reports suggest that Tregs are beneficial to patients with certain types of cancers. Therapeutic strategies to manage Treg capacity to mediate immune dysfunction include depletion, regulatory functional blockade, differentiation blockade, altering trafficking, differentiation diversion, or raising the threshold of anti-cancer effector cells for Treg-mediated regulation. Several clinical trials have shown the feasibility and relative safety of managing Tregs in human cancer, although treatment effects are modest. This chapter will review contemporary knowledge of Tregs in cancers, including origins, mechanisms of action, interactions with other immune cells and strategies for therapeutic management, addresses the major questions facing the field and suggests additional important areas for future research. The focus is on CD4+CD25+Foxp3+ Tregs, but other cancer-associated regulatory cells will be addressed in brief.

UR - http://www.scopus.com/inward/record.url?scp=84949175670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949175670&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4732-0_9

DO - 10.1007/978-1-4614-4732-0_9

M3 - Chapter

AN - SCOPUS:84949175670

SN - 9781461447320

SN - 1461447313

SN - 9781461447313

VL - 9781461447320

SP - 281

EP - 314

BT - Cancer Immunotherapy: Paradigms, Practice and Promise

PB - Springer New York

ER -